Solutions for Healthcare Providers

iStent inject® W

iStent inject® W is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate primary open-angle glaucoma.

Contact Representative
Two iStent inject® W devices that use trabecular micro-bypass technology.
Two iStent inject® W devices that use trabecular micro-bypass technology.

Key Advantages to Using the Device Include:

Minimal Invasiveness

Implanted through a single-entry point, iStent inject® W is implanted during cataract surgery or as a stand-alone procedure. If implanted during cataract surgery, iStent inject® W is implanted through the incision needed for cataract surgery itself.

Improved Outflow

iStent inject® W is designed to create a bypass through the primary blockage site (trabecular meshwork).

Positive Patient Outcomes

Most patients experience a reduction in IOP and a reduction in reliance on glaucoma medication.1-3

Rapid Recovery Time

Patient recovery time is usually rapid, which allows a quick return to normal activities.

Safety Profile

iStent inject® W is effective when implanted in conjunction with cataract surgery or as a stand-alone procedure in patients who require intraocular pressure reduction.1-3

All with the Exceptional Customer Support You’ve Come to Expect from Glaukos

iStent inject® Trabecular Micro-Bypass Instertion illustration.

Mechanism of Action: Restoring the Natural Outflow Pathway

iStent inject® Trabecular Micro-Bypass Instertion illustration.

Delivering two preloaded trabecular micro-bypass stents with a single entry, iStent inject® W is designed to optimise the benefits of MIGS. The iStent inject® W device is designed to improve aqueous outflow through the natural physiological outflow pathway. When the device is implanted in the trabecular meshwork, it is designed to stent open that section of the ocular anatomy to allow aqueous humor to flow from the anterior chamber into Schlemm’s canal. A natural episcleral back pressure of 8-11 mm Hg in the trabecular meshwork reduces the risk of hypotony.4

iStent inject® Trabecular Micro-Bypass Instertion illustration.
The inferonasal-quadrant showing two Glaukos trabecular micro-bypass stents are placed two to three clock hours apart.

Watch How It Works

The inferonasal-quadrant showing two Glaukos trabecular micro-bypass stents are placed two to three clock hours apart.
The inferonasal-quadrant showing two Glaukos trabecular micro-bypass stents are placed two to three clock hours apart.

iStent inject® W System

The iStent inject® W System is engineered to provide an enhanced surgical experience and ensure confident delivery, for every procedure. With a streamlined injector system and next-generation stent design, featuring a wide flange at its base, iStent inject® W is designed to optimise stent visualisation and placement, enhance procedural predictability, and increase peace of mind.

Focused on Excellent Outcomes

See the latest clinical data around iStent inject® W patient outcomes.

View Clinical Data

We’re here to answer questions and provide any additional information you may need.

Request More Info

"*" indicates required fields

Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.

References

  1. Lindstrom R, Lewis R, Hornbeak H, Voskanyan L, Giamporcaro JE, Hovanesian J, Sarkisian S. Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up. Adv Ther 2016;33:2082-2090.
  2. Berdahl J, Voskanyan L, Myers JS, Hornbeak DM, Giamporcaro JE, Katz LJ, Samuelson TW. Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up. Clin Exp Ophthalmol 2017 Nov;45(8):797-802.
  3. Voskanyan L, García-Feijoó J, Belda J, Fea A, Jünemann A, Baudouin C. “Prospective, Unmasked Evaluation of the iStent inject System for Open-Angle Glaucoma: Synergy Trial”. Adv Ther 2014; 31:189-201.
  4. Rosenquist R, Epstein D, Melamed S, Johnson M, Grant WM. Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculectomy. Curr Eye Res. 1989;8:1233-1240.

New Zealand iStent inject® W Important Safety Information

Indication for Use

The iStent inject® W Trabecular Micro-Bypass System (Model G2-W) is intended to reduce intraocular pressure in adult patients diagnosed with mild to moderate primary open-angle glaucoma (POAG) currently treated with ocular hypotensive medication. The device can be implanted with or without cataract surgery.

Contraindications

The device is contraindicated for use in eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations, and in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings

This device has not been studied in patients with uveitic glaucoma. Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients, can enhance the formation or progression of cataract. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. iStent inject® is MR-Conditional, meaning that the device is safe for use in a specified MRI environment under specified conditions; please see labelling for details. Physician training is required prior to use. Do not re-use the stent(s) or injector.

Adverse Events

Postoperative adverse events include but are not limited to: corneal complications including edema, opacification and decompensation, cataract formation (in phakic patients), posterior capsule opacification, stent obstruction, intraocular inflammation (non-pre existing), BCVA loss and IOP increase requiring management with oral or intravenous medications or surgical intervention. Please refer to Directions for Use for additional adverse event information.

Caution

Please reference the Directions For Use labelling for a complete list of contraindications, warnings and adverse events.


iStent infinite® ISI


iStent® ISI


iStent inject® W ISI


Preserflo ISI

Please Select Your Country

Continue